Cancer Cell Panel & In Vitro Oncology Assays

Cancer Cell Panel & In Vitro Oncology Assays

Overview

We offer a diverse in vitro screening panel of over 600 authenticated, well-validated human cancer cell lines across 30 cancer types. Our cancer cell line panel provides powerful tools for cancer research and drug discovery. Key features of the WuXi cancer cell panel include:

• High quality cell banking system: mycoplasma-proof and STR verified
• Single agent and combination compound screening for potency (% inhibition & IC50) and synergy (combination index CI)
• Professional design with stringent quality control of study results
• A database of cell growth curve and Standard of Care (SoC) validation data provides guidance for cell model selection
• 9 drug-resistant cell lines
• Over 150 engineered cell lines
• 95 PDX-derived cell lines
• More than 100 mouse lines, covering 20+ cancer types

Large Scale Human Cancer Cell Lines for Cell Panel Services

A wide range of 600+ human cancer cell lines is available for oncology drug discovery programs. The cell banking system is a two-tiered banking system with mycoplasma testing and STR validation. Established cell growth data and standard of care profiling enhance the quality of study. The table shows the distribution of these human cancer cell lines, sorted by the origins of derived organs/tissues.

Synergistic effects of Compound X with Ibrutinib in TMD8

Potency Correlation of Compounds (kinase assay & cell proliferation assay)

Cell line-derived xenograft (CDX) tumor models

Overview

• A large collection of cell line-derived xenograft (CDX) tumor models
  -Over 320 validated models, SOC data available
• World leading imaging based orthotopic/metastatic CDX platform
  -28 models covering 16 tumor types

Cell Line-Derived Xenograft (CDX) Tumor Models: 320

*: validated with SOC compound

Luciferase Labelled Orthotopic/Metastatic Tumor Models

• Covering 16 tumor types
• Bioluminescent imaging system in SPF barrier

Immuno-oncology

One stop service to enable cancer immunotherapy

Outstanding Platform to Enable Cancer Immunotherapy with One Stop Service

• Immunological function assessment
• Tumor microenvironment analysis
• In vivo efficacy evaluation on animal models
• NGS to understand TCR/BCR Repertoire
• Patient TILs analysis

Immuno-oncology In Vitro Functional Assays

• Immune cell activation assays
  – T/B/NK cell activation
• Macrophage differentiation assays
  – M1/M2 macrophage differentiation
  – DC differentiation
  – MDSC induction
• T cell polarization assays
  – Treg/Th1/Th2/Th17 differentiation
• T cell cytotoxicity assay
  – Cytotoxic T lymphocyte assay (OT-1 system)
• Mixed Lymphocyte Reaction
• Antibody-Drug Conjugate (ADC) binding
• Immune cell suppressive assay
  – MDSC/Treg/Tumor-T suppressive assay
• Antibody mediated immunological assay
  – ADCC/CDC/ADCP

Immuno-oncology In Vitro Technical Competence

Immune primary cell profiling in tumor infiltrating leukocyte (TIL) and other tissues (spleen, blood, lymph node, liver) profiling: (1) Immune cell population analysis (T, B, NK, DC, Myeloid, Macrophage, Granulocyte, CD4+T, CD8+T, Treg, Th1/2/17, naïve/memory/effector T, g/mMDSC, M1/M2, etc.) (2) Functional and intracellular marker analysis (PD-1, PD-L1/2, CTLA-4, TIM-3, LAG-3, OX40, 4-1BB, ICOS, Ki-67, IL-2, IL-17, IFNγ, TNFα, Granzyme B)

Biomarker

• Soluble biomarker – ELISA, ELISPOT
• Cell-based biomarker – FACS
• Tissue-based biomarker – Multiplex IHC
• Gene expression profiling – RNAseq, NanoString

Tumor Infiltrating Lymphocytes (TILs) Analysis on Human and Murine Tumor Tissues

• CD4, CD8, MDSC, M1/M2, DC cell, NK cell, B cell
• PD1, TIM3, LAG3, OX40, 4-1BB
• Treg, Th1,2,3, and17

In Vivo Efficacy Evaluation on Animal Models Syngeneic Murine Models

• Immune-checkpoint humanized models
• Immune-Avatar humanized models PBMC humanized models
• HSC humanized models

TM (Tumor Microenvironment) Analysis for Immunoscore by FACS, IHC and IF

CTLs, NK, Tregs, MDSC, and TAM

Lymphoid Tissue and Peripheral Blood Analysis

• Immune cell populations and subsets – frequency, activation, and differentiation
• Cytokine and chemokine analysis
• Anatomical localization ofin vivo anti-tumor immune responses

Adoptive T Cell Therapy